Our study demonstrates that Ginsenoside Rh2 (GRh2) exerts potent anti-tumor effects against prostate cancer in vitro and in vivo primarily through the induction of mitochondrial damage, subsequently activating two key processes: PINK1/Parkin-mediated mitophagy and ferroptosis. Here, PRKN is linked to prostate carcinoma.